stockrow
Friday 6 November 2026
Export FTRE’s income statement to Excel — free account
Fortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
21.95
1.49
+7.28%
Follow FTRE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.58 | 0.33 | 0.62 | 0.72 | |
P/FCF ratio |
17.82 | 4.63 | 8.33 | 11.15 | |
P/Operating CF |
12.19 | (51.87) | 57.08 | 31.37 | |
P/B ratio |
2.79 | 1.68 | 3.15 | 3.58 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.90 | 0.66 | 0.95 | 1.03 | |
EV/EBITDA |
742.92 | 56.75 | 37.56 | 29.97 | |
EV/Operating CF |
21.60 | 8.10 | 11.13 | 13.59 | |
EV/FCF |
27.76 | 9.39 | 12.80 | 16.03 | |
Quick Ratio |
0.84 | 0.83 | 0.85 | 0.88 | |
Current Ratio |
0.98 | 0.95 | 0.96 | 0.97 | |
Net Debt/EBITDA |
154.08 | 55.24 | 25.75 | 23.85 | |
Debt/Assets |
38.77% | 39.26% | 38.83% | 38.54% | |
Debt/Equity |
1.87 | 2.00 | 2.01 | 1.98 | |
Asset Turnover |
0.87 | 0.93 | 0.96 | 0.97 | |
Operating CF/Net income |
(3.97) | 0.72 | (2.19) | 101.33 | |
Capex/Depreciation |
(0.39) | (0.40) | (0.36) | (0.41) | |
Interest Coverage |
(0.59) | (0.18) | 0.77 | 0.74 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.59% | 15.79% | 15.05% | 15.01% | |
Intangible Assets out of Total Assets |
0.58 | 0.58 | 0.57 | 0.56 | |
Share Based Compensation of Revenue |
2.24% | 1.79% | 1.86% | 1.74% | |
Graham Net Nets |
(0.80) | (1.45) | (0.77) | (0.66) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(63.25%) | (52.12%) | (5.23%) | (3.68%) | |
Free Cash Flow Yield |
5.61% | 21.59% | 12.00% | 8.97% | |
Revenue per Share |
7.24 | 6.80 | 7.15 | 7.23 | |
Operating CF per Share |
1.42 | (0.18) | 0.30 | 0.64 | |
Capex per Share |
(0.08) | (0.09) | (0.07) | (0.09) | |
Free Cash Flow per Share |
1.33 | (0.27) | 0.23 | 0.55 | |
Cash per Share |
1.91 | 1.58 | 1.78 | 2.31 | |
Shareholders Equity per Share |
6.18 | 5.62 | 5.53 | 5.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.18 | 5.62 | 5.53 | 5.57 | |
Free Cash Flow |
121.60 | (25.00) | 21.90 | 52.50 | |
Working Capital |
(16.10) | (47.60) | (40.10) | (30.60) | |
Capital Expenditures |
(7.50) | (8.00) | (7.00) | (8.30) | |
Net Current Asset Value |
(1,255.00) | (1,276.00) | (1,267.10) | (1,253.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 214.21 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 149.00 | |
| Other line items | |||||
Average Receivables |
624.60 | 674.30 | 696.80 | 652.15 | |
Average Payables |
83.95 | 90.50 | 73.40 | 51.25 | |
Average Assets |
3,147.45 | 2,902.25 | 2,775.00 | 2,740.15 | |
Average Common Equity |
962.95 | 692.35 | 556.70 | 556.55 |
Columns are period end dates · fundamentals updated 2 Nov 2026